GSK Returns Rights to Wave's Pioneering RNA Editing Therapy, Citing Strategic Focus Shift
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.